InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Begin Proposed Public Offering
November 10, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced that it is starting an underwritten public offering; the offering is comprised of ANPC’s American Depositary Shares and is subject to market and other conditions. The announcement noted that there is […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Participate in Q4 Virtual Investor Summit
November 8, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced its participation in the Q4 Virtual Investor Summit, slated for Nov. 16–17, 2021. According to the announcement, AnPac head of investor relations, Phil Case, will present at the two-day event; AnPac’s […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging CDA Technology for Critical Early Cancer Detection
October 29, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, since 2015 has commercially proven out its concepts through the development and sale of its cancer detection technology, Cancer Differentiation Analysis (“CDA”) for early detection of pre-cancerous disease and cancer. “The company has published numerous reports of clinical study results […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) Unique Platform Offering Comprehensive Blood Test Data, New Approach to Disease Screening
October 22, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. The CDA platform, in which technology is […]
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Among Leading Biotech Companies Innovating the Field of Early Cancer Screening and Detection
October 12, 2021
Blood and genomic testing are becoming preferable means of early cancer screening and detection Leaders innovating this niche of the medical industry include AnPac Bio, Grail, Thrive and Guardant AnPac Bio-Medical’s testing features a database of more than 200,000 commercial and research multi-cancer test samples (probably the largest multi-cancer test data base) that detect up […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Stands Distinct in World of Cancer Prevention, Treatment
October 11, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter and multi-cancer screening. The […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Study Results Confirming Correlation Between CDA Score, Risk of Cancer
October 4, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reached a significant milestone and positive result in its general-population, cancer-risk assessment tests and subsequent follow-up study. At the end of September 2021, healthcare providers confirmed more than 2,000 cancer, precancer […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) First Half Revenue Numbers Up by 128.5%, Non-GAAP Loss Down by 18.3%
October 1, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has released it unaudited financial results for the six months ended June 30, 2021. Highlights of the report include total revenues reaching an estimated $1.4 million, an increase of 128.5% compared to the same period in 2020; gross profit margin […]
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) 10 Years in the Making: Innovation Leads to Multi (Pan)-Cancer Screening
September 28, 2021
After ten years, the concept of (multi)pan-cancer screening pioneered by AnPac Bio-Medical Science Co., Ltd. (AnPac Bio) has finally been accepted and the industry is shifting toward early screening technology that detects multiple cancers in blood at one time. In 2010, AnPac Bio proposed the theory of multi-cancer screening. At the time, the industry was […]
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leading the Way in Early Cancer Detection Space
September 27, 2021
Up to 50% of cancer is preventable, while other types can be detected or treated early, often resulting in complete remission for patients AnPac Bio-Medical Science Co., Ltd. uses blood-based testing to detect many types of cancer (multi-cancer tests) and pre-cancer diseases, predicting its potential to occur in the future Company’s proprietary CDA technology is […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CDA Technology Detects Risk of Over 25 Different Cancer Types
September 24, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a recognized innovator and leader in the field of early cancer screening and detection. Its core product and proven revenue generator, the pioneering Cancer Differentiation Analysis (“CDA”) platform, offers novel capabilities by looking for signals to help it assess […]
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receives College of American Pathologists Accreditation for U.S. Laboratory
September 22, 2021
AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021 Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection and screening technology, with over 200,000 samples and cases to serve as a way of approaching cancer screening Company’s ownership […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging Partnerships to Save Patients’ Lives, Broaden Product Pipeline
September 14, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, recently announced a cooperation agreement with Roche Pharmaceuticals China, a subsidiary of Roche Holdings AG, to explore novel medical solutions. Under the agreement, “both parties plan to utilize AnPac Bio’s Cancer Differentiation Analysis (‘CDA’) cancer detection technology and Roche’s FoundationOne […]
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for National Medical Products Administration Registration of Early-Warning Cancer Technology with a Record 11 Tumor Types Under Formal Medical Device Product Registration
September 13, 2021
AnPac Bio-Medical Science Co., Ltd. has developed its proprietary Cancer Differentiation Analysis (“CDA”) technology to detect biophysical signals as an alternative early disease indicator to blood-based biomarker testing for cancer The company has laboratories and R&D facilities in China equipped for CDA testing and cancer biochemical testing, as well as a CLIA/CAP accredited laboratory in […]
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Symposium Highlights the Application of Biophysical Technology in Cancer Prevention and Treatment
September 8, 2021
AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021 The symposium included attendees from various hospitals, universities, and Fortune 500 companies, including Thermo Fisher Scientific and AnPac Bio’s contract partner Roche Pharmaceuticals China A recent report […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase in Subsidiary Holding
September 7, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary AnPac Bio-Medical Science (Lishui) Co. Ltd. has increased its holding in AnPai (Shanghai) Healthcare Management Consultant Co. Ltd., one of its subsidiaries; the increase came after approval was granted by the company audit committee and board of directors. The company announced that in late August 2021 it finalized the […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CLIA Laboratory Receives Accreditation from the College of American Pathologists
August 30, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its Philadelphia, Pennsylvania-based Clinical Laboratory Improvement Amendments (“CLIA”) certified laboratory has received accreditation from the College of American Pathologists (“CAP”). The U.S. federal government recognizes the CAP Laboratory Accreditation Program, initiated in the early 1960s, as being […]
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names CEO of AnPac Bio U.S. to Drive Adoption of Early Cancer Detection Technology
August 26, 2021
Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocols AnPac Bio’s proprietary technology screens for a variety of biophysical properties and analyzes the results to establish risk factors for tumor development before tumor cells begin […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for Registration Testing of Its Multicancer CDA Device
August 23, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has filed with China’s National Medical Products Administration (“NMPA”) for registration testing of its class III, multicancer detection medical device; the device, which has been tested and evaluated extensively, features AnPac’s proprietary Cancer Differentiation Analysis Technology (“CDA”). The company […]
AnPac Bio Successfully Completes Major PreClinical Study, Files with National Medical Products Administration (NMPA) for Registration Testing of Its Multi-Cancer CDA Device
August 23, 2021
PHILADELPHIA, Aug. 23, 2021 (GLOBE NEWSWIRE) — via Investor Wire – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announces that the Company filed with China’s National Medical Products Administration (NMPA) on Aug. 19, 2021, for registration testing […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Seasoned Professional as US CEO
August 17, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has appointed life-sciences veteran and biomedical scientist Dr. Sunil Pandit as its new U.S. CEO; the appointment is effective as of Aug. 16, 2021. The company noted that Pandit will lead AnPac Bio’s U.S. research and development efforts, as […]
AnPac Bio Taps Life Sciences and Diagnostics Veteran as US CEO
August 17, 2021
PHILADELPHIA, Aug. 17, 2021 (GLOBE NEWSWIRE) — via InvestorWire — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announces that it has hired Dr. Sunil Pandit, a successful life sciences veteran and highly accomplished bio-medical scientist, as its […]
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces New Cooperative and Partnership Agreements, and further Strengthens Board of Directors
August 17, 2021
Cooperation and partnership discussions: AnPac Bio has reported major corporations in the medical industry include Roche Pharmaceuticals China and Advanced Life Therapeutics Co., Ltd AnPac Bio holds 40% minority equity in Advanced Life Therapeutics, performing contract R&D on integrated circuit-based components for cancer treatment medical devices AnPac Bio’s board now includes Mr. Chao Feng who […]
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Featured in Coverage of Investor Summit Group’s Q3 Virtual Event
August 12, 2021
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, […]
Anpac Bio Continues Growth Trajectory
August 12, 2021
In recent years, advances in technology have led to demand for early cancer testing and screening methods that are less invasive and lower cost. Insurance companies have accepted that traditional testing methods are labor intensive and are not ideal as the first line of defense when screening and diagnosing cancer. This has opened a multi-billion-dollar […]
InvestorNewsBreaks – Why AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’
August 11, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is focused on early cancer screening and detection. With an aim of changing the way people approach cancer screening, the company develops, distributes and deploys accessible early disease detection devices. “AnPac Bio-Medical is a highly innovative company and an early […]
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Testing Volume Increase for First Half of 2021
August 6, 2021
Total number of paid tests and paid cancer tests increased significantly in Q2 over Q1 The company’s approach to multi-cancer screening is called Cancer Differentiation Analysis (“CDA”) that is powered by a database of over 200,000 samples and cases, changing the way to approach disease and cancer screenings The global cancer diagnostics market size is […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Enters Strategic Collaboration to Explore Innovative Products and Medical Solutions
August 5, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced its entry into a cooperation agreement with Roche Pharmaceuticals China (“Roche”) to leverage both parties’ advantages and sources to explore novel health care and medical solutions and collaboration models in early cancer screening, early diagnosis and early treatment. […]
AnPac Bio-Science Co., Ltd. Continues To Build On Its Success With What Many Thought Impossible – Multiple Cancer Screening
August 4, 2021
Summary After ten years of hard work, the pan-cancer screening concept and efforts led by AnPac Bio-Science Co., Ltd. (“AnPac Bio”; NASDAQ: ANPC) since 2010 is gaining market acceptance and traction. AnPac Bio’s cancer screening technology uses sensors fabricated by integrated circuit (IC) process to detect multiple cancers in the blood at the same time. […]
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’
August 2, 2021
AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people approach cancer screening CDA is powered by a database of over 200,000 samples and cases, providing a new way to […]
InvestorNewsBreaks – AnPac Bio-Medical Science (NASDAQ: ANPC) Names New Independent Director
July 23, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced the appointment of Mr. Chao Feng as an independent director. Mr. Feng, a seasoned executive that has previously worked for two US Fortune 500 Companies in China, will be succeeding Ms. Lin Yu who resigned as a […]